Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 5, 2009

Broad Institute Buys Another 30 Genome Analyzers from Illumina

  • The Broad Institute purchased 30 additional Genome Analyzers from Illumina. It has thus increased its total installed base of Illumina systems to 89. 

    The Genome Analyzer offers a range of supported applications including whole-transcriptome profiling and discovery, epigenetic studies, whole genome resequencing, de novo sequencing, targeted resequencing, ChIP-sequencing, bi-sulfite sequencing (DNA methylation), small RNA, mRNA, tag profiling, and metagenomics.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »